IN8bio Inc
in8bio.comIN8bio Inc (NASDAQ: INAB) is a clinical-stage biotechnology company developing cell therapy product candidates, with a focus on gamma-delta T cell therapies for cancer treatment. The company has generated no product revenue since inception and funds operations through financing activities rather than product sales. As of the 10-K filed March 12, 2026, IN8bio reported a net loss of $19.4 million and cash used in operating activities of $12.7 million for the year ended December 31, 2025. The company relies entirely on third-party contract manufacturers and GMP cell therapy laboratory facilities for production of its product candidates, with manufacturing agreements structured on a per-patient basis. IN8bio operates in the biotechnology sector, competing against other companies developing novel cell therapies and proprietary cancer treatments. CEO William Ho and CFO Patrick McCall lead the company. IN8bio has not yet commercialized any product candidates and expects to seek third-party collaborators or self-fund commercialization if and when any product receives marketing approval.
Products & Services
Clinical-stage gamma-delta T cell therapy product candidates in Phase 1 and Phase 2/3 clinical trials. No marketed products as of the 10-K filed March 12, 2026.
Revenue Model
No product revenue has been generated since inception as of the year ended December 31, 2025. Operations are funded through financing activities. Future revenue, if any, is expected to depend on product approvals and potential third-party commercialization partnerships.
Customers & Markets
No commercial customers as of December 31, 2025. End market is oncology, targeting cancer patients. Clinical trial participants are the current subjects of the company's development-stage programs.
Geographic Exposure
Primarily United States-based operations, with regulatory focus on FDA approval pathways. Some reference to regulatory agencies in other jurisdictions, but no specific geographic revenue breakdown disclosed in the excerpts.
Financial Snapshot
Loading...
